Summary of Whitehawk Therapeutics Conference Call Company Overview - Company Name: Whitehawk Therapeutics (formerly Adi Biosciences) [4] - CEO: Dave Lennon [2] - Focus: Advanced Antibody-Drug Conjugates (ADCs) targeting various cancers [2][4] Key Developments - Strategic Transactions: - In-licensed three ADCs from Ushia Biologics [4] - Divested Fiaro to Kaken Pharmaceuticals [4] - Completed a $100 million PIPE financing [4] - Transition to Whitehawk: The company relaunched as Whitehawk Therapeutics in March 2025, focusing on ADC therapeutics [4][5] ADC Portfolio - Portfolio Composition: Three ADC assets targeting validated tumor markers: PTK7, MUC16, and SCC6 [8][9] - Clinical Strategy: - All three INDs (Investigational New Drug applications) expected to be filed by mid-2026 [7][17] - Cash reserves of approximately $185 million to fund operations into 2028 [7] Targeted Tumor Markers 1. PTK7: - Overexpressed in various tumors, particularly in non-small cell lung cancer and gynecological cancers [9][18] - No approved ADCs targeting PTK7 currently exist [9] - Expected to have a significant patient population, with 60-70% of patients expressing PTK7 during their cancer journey [18] 2. MUC16: - Targets a glycoprotein overexpressed in female-origin tumors, including ovarian cancer [10][21] - Previous studies by Genentech showed high response rates but required high doses due to the antigen sink effect [21][22] - Whitehawk's approach targets the membrane-bound portion to avoid this effect [22] 3. SCC6: - Targets a CNS-limited protein overexpressed in neuroendocrine tumors, particularly small cell lung cancer [11][24] - Whitehawk plans to utilize a biparatopic approach to enhance efficacy and safety [25] Technology Platform - CPT113: Advanced ADC technology platform with a proprietary TOPO-one inhibitor payload and stable linker chemistry [12][13] - Advantages: - Improved stability and reduced off-target toxicity compared to first-generation ADCs [13][14] - Expected efficacy gains of 15-30% over existing therapies [16] Market Potential - Expansion Opportunities: Significant unmet needs in targeted cancers, with potential for expansion into various indications [17][18] - Competitive Landscape: Acknowledgment of competition from other ADCs, particularly from AbbVie, but with a focus on improving safety and efficacy profiles [34] Financial Outlook - Cash Runway: Sufficient funds to support operations and clinical trials through early 2028 [27][41] - Future Funding: No plans to raise additional funds until clarity on the portfolio's next steps is achieved [43] Conclusion - Whitehawk Therapeutics is positioned to leverage its advanced ADC technology and validated tumor targets to address significant unmet needs in cancer treatment, with a well-capitalized structure to support its clinical development plans [26][27]
Whitehawk Therapeutics (AADI) 2025 Conference Transcript